Market cap rises widespread among industry's biggest players in 2021

1 February 2022

The top 20 global innovative biopharma companies had a favorable year in 2021, reporting a 24.9% growth in aggregate market capitalization (MCAP), according to GlobalData.

This figure rose from $2.8 trillion on December 31, 2020 to $3.4 trillion as of December 31, 2021, the data provider’s research found.

A positive year-on-year (YoY) MCAP growth was reported for 14 of the top players, with five companies—BioNTech (Nasdaq: BNTX) (218.5%), Moderna (Nasdaq: MRNA) (149.1%), Novo Nordisk (NOVN: VX) (71.8%), Eli Lilly (NYSE: LLY) (63.6%) and Pfizer (NYSE: PFE) (61.9%) - demonstrating more than 50% growth in their MCAP in 2021.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK